Metabolic syndrome: is Nlrp3 inflammasome a trigger or a target of insulin resistance?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21566220.
- Also identified by DOI 10.1161/RES.0b013e318220b57b and PMC identifier 3660550.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Nlrp3 inflammasome has recently been implicated in the development of the metabolic syndrome through the impairment of adipose tissue insulin sensitivity. Recent literature associates Nlrp3 activation with much pathology caused by prolonged insulin resistance state, therefore establishing Nlrp3 as a promising therapeutic target for type-2-diabetes treatment.
Medical subject headings
- Carrier Proteins
- Inflammasomes
- Insulin Resistance
- Metabolic Syndrome